Key facts
- This page summarizes David D. Allison's Form 4 filing for CinCor Pharma, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Oct 2022, 16:28.
David D. Allison - 07 Oct 2022 Form 4 Insider Report for CinCor Pharma, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 07 Oct 2022
- Net transaction value
- +$12,497
- SEC form
- 4
- Accepted by SEC
- 12 Oct 2022, 16:28:38 UTC
- Prior SEC filing
- 20 Jul 2022
- Next SEC filing
- 10 Jan 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Cathy Rude, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David D. Allison filed Form 4 for CinCor Pharma, Inc. on 12 Oct 2022.
Change
- Previous filing in this sequence was filed on 20 Jul 2022.
- Current net transaction value: +$12,497.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CINC
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $12,497
- Shares
- +524
- Change %
- Price
- $23.85
- Shares after
- 524
- Date
- 07 Oct 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 524
- Exercise price
- $33.49
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option was issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of retainer fees of $12,500.